Research Antibodies Market size is estimated at USD 4.8 billion in 2024 and is predicted to exceed USD 9.5 billion by the end of 2037, registering over 5.9% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of research antibodies is evaluated at USD 5 billion.
Research academia and industry collaboration has grown manifold in the past few years. This trend has helped the market growth of research antibodies flourish. In 2019, Absolute Antibody partnered with the University of Georgia for medical applications of research antibodies developed at the university. Such collaborative efforts boost the speed of research efforts and provide licensing rights of breakthrough research to key research antibodies market players which can be effectively applied in commercial applications. For instance, in January 2023, Ono Pharmaceuticals Co., Ltd entered a collaboration agreement with Monash University to develop antibodies for G Protein-coupled receptors (GPCRs). Through this, the company will obtain the worldwide rights to commercialize existing antibodies developed by Monash along with any new antibodies arising from research.
Research antibodies are essential detection tools to understand cell functions. Researchers can use antibodies to identify how a cell function has gone wrong during its life cycle. For instance, a National Library of Medicine report in 2023, stated monoclonal antibodies (mAbs) are rapidly entering clinical therapeutics and have shown promise against HIV and malaria. As research and development continue to develop, the commercial applications of antibodies will grow significantly.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.9% |
|
Base Year Market Size (2024) |
USD 4.8 billion |
|
Forecast Year Market Size (2037) |
USD 9.5 billion |
|
Regional Scope |
|
Product (Primary Antibodies, Secondary Antibodies)
Primary antibodies segment is anticipated to dominate over 77.3% research antibodies market share by 2037. The key segment driver is the rising demand for tools to study and understand biological processes. These antibodies are used for research applications for immunohistochemistry, flow cytometry, and western blotting among others. The segment has also been boosted by the expansion of research activities in biotechnology and genomics. For instance, in 2021, the University of Cambridge developed single-domain antibodies (sdAbs) that can be used for treating acute coronary syndrome.
The secondary antibodies segment is expected to have considerable growth during the forecast period due to their role in improving detection sensitivity. The development of advanced detection techniques such as flow cytometry and fluorescence microscopy has enabled the growth of this segment. Key players in this segment are actively trying to improve measurement accuracy and reduce background noise. For example, Invitrogen Alexa Fluor Plus secondary antibodies were developed by ThermoFisher for a high signal-to-noise ratio.
Source (Rabbit, Mouse, Goat)
The rabbit monoclonal antibody segment in research antibodies market is expected to hold a significant revenue share during the forecast period owing to its versatility. Rabbit monoclonal antibodies are used in various research techniques such as flow cytometry, immunohistochemistry, and western blotting. The adaptability increases their applications, thereby boosting research antibodies market growth. The key players in this segment are expanding their portfolio and investing in research & development activities to expand their market shares.
In February 2023, Roche launched the IDH1 R132H rabbit monoclonal primary antibody to identify mutation strains in patients diagnosed with brain tumors. In November 2022, Bruker Cellular Analysis launched Opto Memory B Discovery Rabbit Worfklow which assists in the discovery of rabbit antibodies suitable for research and diagnostics.
Type (Monoclonal Antibodies, Polyclonal Antibodies)
The monoclonal antibodies segment in research antibodies market is expected to register rapid revenue CAGR between 2025 and 2037 due to the increasing prevalence of chronic diseases, advancements in biotechnology, and the growing need for personalized medicine. Polyclonal antibodies help in testing for diseases such as herpes and HIV. The increased investments in research and development have enabled the primary market players of this segment to access new research breakthroughs. For instance, in May 2024, AstraZeneca’s Sipavibart trial demonstrated a decreasing level of COVID-19 symptoms in an immunocompromised population.
The polyclonal antibodies segment is also poised for significant growth during the forecast period owing to its cost-effectiveness. Advancements in antigen preparation have enabled the development of polyclonal antibodies with improved specificity. For instance, in 2021, ACTG announced the graduation of a novel polyclonal antibody therapy, SAB 185, for a phase 3 study.
Our in-depth analysis of the global research antibodies market includes the following segments:
|
Product |
|
|
Source |
|
|
Type |
|
|
Technology |
|
|
Application |
|
|
End user |
|
North America Market Statistics
North America in research antibodies market is likely to hold more than 40.7% revenue share by 2037, due to robust technological infrastructure, increasing investment by government in research & development, and strong regulatory frameworks.
In the U.S., biotechnology hubs like San Francisco Bay Area and San Diego contribute to a research-oriented ecosystem, boosting research antibodies market growth. Another significant driver is the presence of robust infrastructure, world-class universities, and top pharmaceutical companies which increase the demand for research antibodies. The US Food and Drug Administration (FDA) plays a stellar role in helping the commercialization of research antibodies while ensuring quality control. For instance, FDA approved the third anti-amyloid antibody for Alzheimer's by Eli Lilly in July 2024, and GSK’s B7 H3 targeted antibody drug in August 2024.
Canada holds a considerable share in the research antibodies market due to the extensive government support in the life sciences industry and a strong technological infrastructure. In October 2023, the government invested USD 15 million to create a nationwide genome library. The government is focused on creating a genome library for personalized medicines to cater to the rising demand for research antibodies. For instance, in February 2024, AbbVie and OSE immunotherapeutic announced a partnership to research and develop a novel monoclonal antibody that will help fight chronic inflammation.
APAC Market Analysis
Asia Pacific is projected to witness a massive surge in the research antibodies market during the forecast period due to drivers such as increased investment in the healthcare sector of emerging economies, increasing spending on healthcare, and the rising trajectory of chronic diseases in the region.
In India, rising cases of chronic diseases such as cancer have boosted the demand for research antibodies. The emerging economy now has a significant population with high spending on healthcare, thereby increasing the demand for advanced care. This drives the need for research antibodies for personalized medicines. Key market players are capitalizing on the demand. For example, in March 2024, Roche launched a monoclonal antibody for two critical eye diseases in the country named Vabysmo.
China holds a significant revenue share in the APAC research antibodies market owing to its rapid economic development, increasing investments in research, and large domestic population. The regulatory approval ecosystem in China is robust and has led to a smooth approval process for products. In 2021, Mabwell Bioscience’s Anti St2 antibody was approved for clinical trial by the Centre for Drug Evaluation (CDE). The government invested USD 8 billion in its precision medicine plan which boosted the demand for research antibodies. In 2024, Duoning Biotech announced the commercialization of a single cell sorting system for antibody discovery.
Japan is a significant player in the APAC research antibodies market and is expected to hold a strong revenue share during the forecast period owing to rising government investments in research and focus on precision medicine due to the rapidly aging society. Recently, in March 2024, AstraZeneca’s Trugap was approved by the Ministry of Health, Labour and Welfare (MHLW) for recurrent PIK3CA.
The research antibodies market is competitive with the presence of global and regional players and new players venturing in for the market share. The significant growth potential is owed to the rapid advancements in biotechnology globally along with rising demand for precision medicines.
Some of the key players in the market are:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?